董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nancy Stagliano | 女 | Chairman of the Board and Director | 59 | 10.00万 | 63.90 | 2026-08-01 |
| Matthew Fust | 男 | Director | 62 | 4.50万 | 13.68 | 2026-08-01 |
| Beth Seidenberg | 女 | Director | 69 | 未披露 | 未持股 | 2026-08-01 |
| Quehuong Dong | 女 | Chief Executive Officer and Director and President | 44 | 101.80万 | 185.47 | 2026-08-01 |
| Carl L. Gordon | 男 | Director | 61 | 未披露 | 555.18 | 2026-08-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary S. Koe | 男 | Chief Technical Officer | 62 | 71.19万 | 44.45 | 2026-08-01 |
| Kim Hien Dao | 女 | Chief Medical Officer | 53 | 54.71万 | 54.72 | 2026-08-01 |
| Chris Clark | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2026-08-01 |
| Graham Parry | 男 | Chief Scientific Officer | 62 | 未披露 | 未持股 | 2026-08-01 |
| Quehuong Dong | 女 | Chief Executive Officer and Director and President | 44 | 101.80万 | 185.47 | 2026-08-01 |
董事简历
中英对照 | 中文 | 英文- Nancy Stagliano
-
Nancy Stagliano自2019年3月起担任Electra Therapeutics，Inc.董事长兼Electra Therapeutics，Inc.董事会成员。Stagliano博士自2018年10月起担任Neuron23董事会主席，自2020年10月起担任Neuron23首席执行官。Stagliano博士还自2018年6月起担任Star Therapeutics的董事会主席。此外，斯塔利亚诺博士自2026年1月起担任私营生物技术公司Sundance Biosciences，Inc.的执行主席。Stagliano博士此前曾担任True North的首席执行官，直到2017年被Bioverativ，Inc.收购。在此之前，斯塔利亚诺博士从2011年开始担任iPierian，Inc.的首席执行官，这是一家专注于神经退行性疾病的私营生物技术公司，直到2014年被百时美施贵宝公司（Bristol Myers Squibb）收购。她还曾于2008年至2011年担任上市临床阶段生物制药公司CytomX医疗，Inc.的首席执行官。斯塔利亚诺博士在迈阿密大学医学院获得神经科学博士学位，并在哈佛医学院完成了博士后研究，以及生物医学工程硕士和电气工程学士学位，均来自德雷塞尔大学。
Nancy Stagliano has served as Electra Therapeutics, Inc.'s Chairperson and member of Electra Therapeutics, Inc.'s board of directors since March 2019. Dr. Stagliano has served as the chair of the board of directors of Neuron23 since October 2018 and as Chief Executive Officer of Neuron23 since October 2020. Dr. Stagliano has also served as chair of the board of directors of Star Therapeutics since June 2018. In addition, Dr. Stagliano has served as executive chair of Sundance Biosciences, Inc., a privately held biotechnology company, since January 2026. Dr. Stagliano previously served as Chief Executive Officer of True North until its acquisition by Bioverativ, Inc. in 2017. Prior to that, Dr. Stagliano served as Chief Executive Officer of iPierian, Inc., a privately held biotechnology company focused on neurodegenerative disease, from 2011 until its acquisition by Bristol Myers Squibb Company (Bristol Myers Squibb) in 2014. She also served as Chief Executive Officer of CytomX Therapeutics, Inc., a publicly held clinical stage biopharmaceutical company, from 2008 to 2011. Dr. Stagliano earned her Ph.D. in neuroscience from the University of Miami School of Medicine and completed a postdoctoral fellowship at Harvard Medical School, as well as an M.S. in biomedical engineering and a B.S. in electrical engineering, both from Drexel University. - Nancy Stagliano自2019年3月起担任Electra Therapeutics，Inc.董事长兼Electra Therapeutics，Inc.董事会成员。Stagliano博士自2018年10月起担任Neuron23董事会主席，自2020年10月起担任Neuron23首席执行官。Stagliano博士还自2018年6月起担任Star Therapeutics的董事会主席。此外，斯塔利亚诺博士自2026年1月起担任私营生物技术公司Sundance Biosciences，Inc.的执行主席。Stagliano博士此前曾担任True North的首席执行官，直到2017年被Bioverativ，Inc.收购。在此之前，斯塔利亚诺博士从2011年开始担任iPierian，Inc.的首席执行官，这是一家专注于神经退行性疾病的私营生物技术公司，直到2014年被百时美施贵宝公司（Bristol Myers Squibb）收购。她还曾于2008年至2011年担任上市临床阶段生物制药公司CytomX医疗，Inc.的首席执行官。斯塔利亚诺博士在迈阿密大学医学院获得神经科学博士学位，并在哈佛医学院完成了博士后研究，以及生物医学工程硕士和电气工程学士学位，均来自德雷塞尔大学。
- Nancy Stagliano has served as Electra Therapeutics, Inc.'s Chairperson and member of Electra Therapeutics, Inc.'s board of directors since March 2019. Dr. Stagliano has served as the chair of the board of directors of Neuron23 since October 2018 and as Chief Executive Officer of Neuron23 since October 2020. Dr. Stagliano has also served as chair of the board of directors of Star Therapeutics since June 2018. In addition, Dr. Stagliano has served as executive chair of Sundance Biosciences, Inc., a privately held biotechnology company, since January 2026. Dr. Stagliano previously served as Chief Executive Officer of True North until its acquisition by Bioverativ, Inc. in 2017. Prior to that, Dr. Stagliano served as Chief Executive Officer of iPierian, Inc., a privately held biotechnology company focused on neurodegenerative disease, from 2011 until its acquisition by Bristol Myers Squibb Company (Bristol Myers Squibb) in 2014. She also served as Chief Executive Officer of CytomX Therapeutics, Inc., a publicly held clinical stage biopharmaceutical company, from 2008 to 2011. Dr. Stagliano earned her Ph.D. in neuroscience from the University of Miami School of Medicine and completed a postdoctoral fellowship at Harvard Medical School, as well as an M.S. in biomedical engineering and a B.S. in electrical engineering, both from Drexel University.
- Matthew Fust
-
Matthew Fust自2023年11月起担任Electra Therapeutics，Inc.董事会成员。Fust先生自2014年3月起在Atara生物治疗，Inc.董事会任职，自2018年3月起在Crinetics制药，自2014年1月起在TERM1，Inc.，自2014年1月起在Ultragenyx药业，Inc.，自2020年12月起在Neumora Therapeutics，Inc.，均为公众持股的生物技术公司。Fust先生此前曾担任奥尼斯医药（一家上市生物制药公司）的执行副总裁兼首席财务官，自2009年1月起，通过该公司于2013年10月被安进（TERM3）收购。Fust先生继续担任安进的员工至2014年1月。从2003年5月到2008年12月，Fust先生在爵士制药制药公司（一家上市的专业制药公司）担任首席财务官。福斯特先生获得了斯坦福大学商学院的工商管理硕士学位和明尼苏达大学德卢斯分校的会计学学士学位。
Matthew Fust has served as a member of Electra Therapeutics, Inc.'s board of directors since November 2023. Mr. Fust has served on the board of directors of Atara Biotherapeutics, Inc. since March 2014, Crinetics Pharmaceuticals, Inc. since March 2018, Ultragenyx Pharmaceutical, Inc. since January 2014, and Neumora Therapeutics, Inc. since December 2020, each of which are publicly held biotechnology companies. Mr. Fust was previously Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from January 2009 through its acquisition by Amgen Inc. (Amgen) in October 2013. Mr. Fust continued as an employee of Amgen until January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a publicly held specialty pharmaceutical company. Mr. Fust earned his M.B.A. from the Stanford Graduate School of Business and his B.A. in Accounting from the University of Minnesota Duluth. - Matthew Fust自2023年11月起担任Electra Therapeutics，Inc.董事会成员。Fust先生自2014年3月起在Atara生物治疗，Inc.董事会任职，自2018年3月起在Crinetics制药，自2014年1月起在TERM1，Inc.，自2014年1月起在Ultragenyx药业，Inc.，自2020年12月起在Neumora Therapeutics，Inc.，均为公众持股的生物技术公司。Fust先生此前曾担任奥尼斯医药（一家上市生物制药公司）的执行副总裁兼首席财务官，自2009年1月起，通过该公司于2013年10月被安进（TERM3）收购。Fust先生继续担任安进的员工至2014年1月。从2003年5月到2008年12月，Fust先生在爵士制药制药公司（一家上市的专业制药公司）担任首席财务官。福斯特先生获得了斯坦福大学商学院的工商管理硕士学位和明尼苏达大学德卢斯分校的会计学学士学位。
- Matthew Fust has served as a member of Electra Therapeutics, Inc.'s board of directors since November 2023. Mr. Fust has served on the board of directors of Atara Biotherapeutics, Inc. since March 2014, Crinetics Pharmaceuticals, Inc. since March 2018, Ultragenyx Pharmaceutical, Inc. since January 2014, and Neumora Therapeutics, Inc. since December 2020, each of which are publicly held biotechnology companies. Mr. Fust was previously Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from January 2009 through its acquisition by Amgen Inc. (Amgen) in October 2013. Mr. Fust continued as an employee of Amgen until January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a publicly held specialty pharmaceutical company. Mr. Fust earned his M.B.A. from the Stanford Graduate School of Business and his B.A. in Accounting from the University of Minnesota Duluth.
- Beth Seidenberg
-
Beth Seidenberg自2019年3月起担任Electra Therapeutics，Inc.董事会成员。Seidenberg博士是生命科学风险投资公司Westlake BioPartners的创始董事总经理，该公司于2018年9月成立。Seidenberg博士还是风险投资公司Kleiner Perkins Caufield和Byers，LLC的普通合伙人，自2005年5月以来，她主要专注于生命科学投资。2002年2月至2004年12月，Seidenberg博士在上市生物技术公司安进担任高级副总裁、全球发展主管和首席医疗官。在此之前，塞登伯格博士曾在上市生物制药公司百时美施贵宝和上市生物制药公司默克制药公司担任研发高级管理人员。Seidenberg博士曾担任Latigo Biotherapeutics，Inc.的董事会成员，Latigo Biotherapeutics，Inc.是一家公众持股的生物制药公司，自2024年7月起，Vera Therapeutics, Inc.是一家公众持股的生物技术公司，自2016年6月起，Kyverna Therapeutics，Inc.是一家公众持股的生物制药公司，自2018年9月起，Sagimet Biosciences Inc.是一家公众持股的生物技术公司，自2007年4月起，以及其他几家私人持股的生命科学公司。Seidenberg博士此前曾于2020年10月至2025年5月在上市生物制药公司Acelyrin，Inc.的董事会任职，于2012年8月至2023年6月在上市生物制药公司Atara Biotherapeutics, Inc.的董事会任职，于2010年5月至2024年11月在上市生育福利管理公司Progyny, Inc.的董事会任职。塞登伯格博士在巴纳德学院获得生物学和人类学学士学位，在迈阿密大学医学院获得医学博士学位，并在约翰霍普金斯大学、乔治华盛顿大学和美国国立卫生研究院完成了研究生培训。
Beth Seidenberg has served as a member of Electra Therapeutics, Inc.'s board of directors since March 2019. Dr. Seidenberg is the founding Managing Director of Westlake BioPartners, a life sciences venture capital firm, formed September 2018. Dr. Seidenberg is also a general partner at Kleiner Perkins Caufield and Byers, LLC, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. From February 2002 to December 2004, Dr. Seidenberg served as the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, a publicly held biotechnology company. Prior to that, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb, a publicly held biopharmaceutical company, and at Merck & Co., Inc., a publicly held biopharmaceutical company. Dr. Seidenberg has served on the board of directors of Latigo Biotherapeutics, Inc., a publicly held biopharmaceutical company, since July 2024, Vera Therapeutics, Inc., a publicly held biotechnology company, since June 2016, Kyverna Therapeutics, Inc., a publicly held biopharmaceutical company, since September 2018, Sagimet Biosciences Inc., a publicly held biotechnology company, since April 2007, and several other privately held life sciences companies. Dr. Seidenberg previously served on the board of directors of Acelyrin, Inc., a publicly held biopharmaceutical company, from October 2020 to May 2025, Atara Biotherapeutics, Inc., a publicly held biopharmaceutical company, from August 2012 to June 2023, and Progyny, Inc., a publicly held fertility benefit management company, from May 2010 to November 2024. Dr. Seidenberg earned her B.A. in Biology and Anthropology from Barnard College and her M.D. from the University of Miami School of Medicine and completed her post graduate training at The Johns Hopkins University, George Washington University, and the National Institutes of Health. - Beth Seidenberg自2019年3月起担任Electra Therapeutics，Inc.董事会成员。Seidenberg博士是生命科学风险投资公司Westlake BioPartners的创始董事总经理，该公司于2018年9月成立。Seidenberg博士还是风险投资公司Kleiner Perkins Caufield和Byers，LLC的普通合伙人，自2005年5月以来，她主要专注于生命科学投资。2002年2月至2004年12月，Seidenberg博士在上市生物技术公司安进担任高级副总裁、全球发展主管和首席医疗官。在此之前，塞登伯格博士曾在上市生物制药公司百时美施贵宝和上市生物制药公司默克制药公司担任研发高级管理人员。Seidenberg博士曾担任Latigo Biotherapeutics，Inc.的董事会成员，Latigo Biotherapeutics，Inc.是一家公众持股的生物制药公司，自2024年7月起，Vera Therapeutics, Inc.是一家公众持股的生物技术公司，自2016年6月起，Kyverna Therapeutics，Inc.是一家公众持股的生物制药公司，自2018年9月起，Sagimet Biosciences Inc.是一家公众持股的生物技术公司，自2007年4月起，以及其他几家私人持股的生命科学公司。Seidenberg博士此前曾于2020年10月至2025年5月在上市生物制药公司Acelyrin，Inc.的董事会任职，于2012年8月至2023年6月在上市生物制药公司Atara Biotherapeutics, Inc.的董事会任职，于2010年5月至2024年11月在上市生育福利管理公司Progyny, Inc.的董事会任职。塞登伯格博士在巴纳德学院获得生物学和人类学学士学位，在迈阿密大学医学院获得医学博士学位，并在约翰霍普金斯大学、乔治华盛顿大学和美国国立卫生研究院完成了研究生培训。
- Beth Seidenberg has served as a member of Electra Therapeutics, Inc.'s board of directors since March 2019. Dr. Seidenberg is the founding Managing Director of Westlake BioPartners, a life sciences venture capital firm, formed September 2018. Dr. Seidenberg is also a general partner at Kleiner Perkins Caufield and Byers, LLC, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. From February 2002 to December 2004, Dr. Seidenberg served as the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, a publicly held biotechnology company. Prior to that, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb, a publicly held biopharmaceutical company, and at Merck & Co., Inc., a publicly held biopharmaceutical company. Dr. Seidenberg has served on the board of directors of Latigo Biotherapeutics, Inc., a publicly held biopharmaceutical company, since July 2024, Vera Therapeutics, Inc., a publicly held biotechnology company, since June 2016, Kyverna Therapeutics, Inc., a publicly held biopharmaceutical company, since September 2018, Sagimet Biosciences Inc., a publicly held biotechnology company, since April 2007, and several other privately held life sciences companies. Dr. Seidenberg previously served on the board of directors of Acelyrin, Inc., a publicly held biopharmaceutical company, from October 2020 to May 2025, Atara Biotherapeutics, Inc., a publicly held biopharmaceutical company, from August 2012 to June 2023, and Progyny, Inc., a publicly held fertility benefit management company, from May 2010 to November 2024. Dr. Seidenberg earned her B.A. in Biology and Anthropology from Barnard College and her M.D. from the University of Miami School of Medicine and completed her post graduate training at The Johns Hopkins University, George Washington University, and the National Institutes of Health.
- Quehuong Dong
-
Quehuong Dong自2023年10月起担任Electra Therapeutics，Inc.总裁兼首席执行官，Electra Therapeutics，Inc.董事会成员。自2023年10月起，她还担任Electra Therapeutics LLC的总裁兼首席执行官和董事会成员。从2019年4月到2023年10月，董博士担任Star Therapeutics，Inc.的首席运营官，Star Therapeutics，Inc.是一家私营生物技术公司（Star Therapeutics），她在该公司的投资组合中担任战略和运营职责。董博士还曾于2019年4月至2023年10月在私营生物技术公司Vega Therapeutics Inc.担任首席运营官。在加入Star Therapeutics之前，Dr. Dong曾在私营生物技术公司True North Therapeutics，Inc.（True North）担任商业发展副总裁。继True North被Bioverativ，Inc.（后被赛诺菲 S.A.（丨赛诺菲）收购）收购后，董博士在上市药企赛诺菲担任补体特许经营的新产品规划负责人。她通过赛诺菲从True North任职的时间为2017年3月至2019年3月。在其职业生涯的早期，董博士曾在公众持股的生物制药公司（吉利德）吉利德科学公司担任HCV市场营销总监。自2022年6月起，董博士还担任Neuron23，Inc.的董事会成员，该公司是一家私营的精准神经病学和免疫疗法公司（Neuron23）。董博士在新墨西哥大学获得了药学博士和工商管理硕士学位，并通过罗格斯大学完成了博士后研究金。
Quehuong Dong has served as Electra Therapeutics, Inc.'s President and Chief Executive Officer and a member of Electra Therapeutics, Inc.'s board of directors since October 2023. She has also served as President and Chief Executive Officer and a member of the board of managers of Electra Therapeutics LLC since October 2023. From April 2019 to October 2023, Dr. Dong served as Chief Operating Officer of Star Therapeutics, Inc., a privately held biotechnology company (Star Therapeutics), where she held strategic and operational responsibilities across the company's portfolio. Dr. Dong also served as Chief Operating Officer at Vega Therapeutics Inc., a privately held biotechnology company, from April 2019 to October 2023. Prior to Star Therapeutics, Dr. Dong served as Vice President of Commercial Development at True North Therapeutics, Inc., a privately held biotechnology company (True North). Following True North's acquisition by Bioverativ, Inc. (which was subsequently acquired by Sanofi S.A. (Sanofi)), Dr. Dong served as Head of New Product Planning for the complement franchise at Sanofi, a publicly held pharmaceutical company. Her tenure from True North through Sanofi was March 2017 to March 2019. Earlier in her career, Dr. Dong served as Director, HCV Marketing at Gilead Sciences, Inc., a publicly held biopharmaceutical company (Gilead). Dr. Dong has also served on the board of directors of Neuron23, Inc., a privately held precision neurology and immunology therapeutics company (Neuron23), since June 2022. Dr. Dong earned her Pharm.D. and M.B.A. at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University. - Quehuong Dong自2023年10月起担任Electra Therapeutics，Inc.总裁兼首席执行官，Electra Therapeutics，Inc.董事会成员。自2023年10月起，她还担任Electra Therapeutics LLC的总裁兼首席执行官和董事会成员。从2019年4月到2023年10月，董博士担任Star Therapeutics，Inc.的首席运营官，Star Therapeutics，Inc.是一家私营生物技术公司（Star Therapeutics），她在该公司的投资组合中担任战略和运营职责。董博士还曾于2019年4月至2023年10月在私营生物技术公司Vega Therapeutics Inc.担任首席运营官。在加入Star Therapeutics之前，Dr. Dong曾在私营生物技术公司True North Therapeutics，Inc.（True North）担任商业发展副总裁。继True North被Bioverativ，Inc.（后被赛诺菲 S.A.（丨赛诺菲）收购）收购后，董博士在上市药企赛诺菲担任补体特许经营的新产品规划负责人。她通过赛诺菲从True North任职的时间为2017年3月至2019年3月。在其职业生涯的早期，董博士曾在公众持股的生物制药公司（吉利德）吉利德科学公司担任HCV市场营销总监。自2022年6月起，董博士还担任Neuron23，Inc.的董事会成员，该公司是一家私营的精准神经病学和免疫疗法公司（Neuron23）。董博士在新墨西哥大学获得了药学博士和工商管理硕士学位，并通过罗格斯大学完成了博士后研究金。
- Quehuong Dong has served as Electra Therapeutics, Inc.'s President and Chief Executive Officer and a member of Electra Therapeutics, Inc.'s board of directors since October 2023. She has also served as President and Chief Executive Officer and a member of the board of managers of Electra Therapeutics LLC since October 2023. From April 2019 to October 2023, Dr. Dong served as Chief Operating Officer of Star Therapeutics, Inc., a privately held biotechnology company (Star Therapeutics), where she held strategic and operational responsibilities across the company's portfolio. Dr. Dong also served as Chief Operating Officer at Vega Therapeutics Inc., a privately held biotechnology company, from April 2019 to October 2023. Prior to Star Therapeutics, Dr. Dong served as Vice President of Commercial Development at True North Therapeutics, Inc., a privately held biotechnology company (True North). Following True North's acquisition by Bioverativ, Inc. (which was subsequently acquired by Sanofi S.A. (Sanofi)), Dr. Dong served as Head of New Product Planning for the complement franchise at Sanofi, a publicly held pharmaceutical company. Her tenure from True North through Sanofi was March 2017 to March 2019. Earlier in her career, Dr. Dong served as Director, HCV Marketing at Gilead Sciences, Inc., a publicly held biopharmaceutical company (Gilead). Dr. Dong has also served on the board of directors of Neuron23, Inc., a privately held precision neurology and immunology therapeutics company (Neuron23), since June 2022. Dr. Dong earned her Pharm.D. and M.B.A. at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University.
- Carl L. Gordon
-
Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University. - Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
- Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
高管简历
中英对照 | 中文 | 英文- Gary S. Koe
Gary S. Koe自2025年5月起担任Electra Therapeutics，Inc.的首席技术官。此前，Koe博士曾于2024年5月至2025年5月担任Electra Therapeutics，Inc.高级副总裁、技术运营主管，并于2023年11月至2024年5月担任副总裁、技术运营主管。Koe博士还曾于2022年3月至2023年11月担任Star Therapeutics技术运营副总裁。Koe博士还在2019年11月至2022年3月期间担任Star Therapeutics的执行董事兼运营主管。在加入Electra Therapeutics，Inc.之前，Koe博士于2015年至2019年在生物技术公司Aravive, Inc.（Aravive）担任技术运营执行董事。Koe博士在加州大学洛杉矶分校获得化学工程博士学位，在加州大学戴维斯分校获得化学工程学士学位。
Gary S. Koe has served as Electra Therapeutics, Inc.'s Chief Technical Officer since May 2025. Previously, Dr. Koe served as Electra Therapeutics, Inc.'s Senior Vice President, Head of Technical Operations from May 2024 to May 2025 and Vice President, Head of Technical Operations from November 2023 to May 2024. Dr. Koe was also Vice President, Technical Operations at Star Therapeutics from March 2022 to November 2023. Dr. Koe also served as Executive Director, Head of Operations at Star Therapeutics from November 2019 to March 2022. Prior to joining Electra Therapeutics, Inc., Dr. Koe served as Executive Director of Technical Operations at Aravive, Inc., a biotechnology company (Aravive), from 2015 to 2019. Dr. Koe earned a Ph.D. in chemical engineering from the University of California, Los Angeles, and his B.S. in chemical engineering from the University of California, Davis.- Gary S. Koe自2025年5月起担任Electra Therapeutics，Inc.的首席技术官。此前，Koe博士曾于2024年5月至2025年5月担任Electra Therapeutics，Inc.高级副总裁、技术运营主管，并于2023年11月至2024年5月担任副总裁、技术运营主管。Koe博士还曾于2022年3月至2023年11月担任Star Therapeutics技术运营副总裁。Koe博士还在2019年11月至2022年3月期间担任Star Therapeutics的执行董事兼运营主管。在加入Electra Therapeutics，Inc.之前，Koe博士于2015年至2019年在生物技术公司Aravive, Inc.（Aravive）担任技术运营执行董事。Koe博士在加州大学洛杉矶分校获得化学工程博士学位，在加州大学戴维斯分校获得化学工程学士学位。
- Gary S. Koe has served as Electra Therapeutics, Inc.'s Chief Technical Officer since May 2025. Previously, Dr. Koe served as Electra Therapeutics, Inc.'s Senior Vice President, Head of Technical Operations from May 2024 to May 2025 and Vice President, Head of Technical Operations from November 2023 to May 2024. Dr. Koe was also Vice President, Technical Operations at Star Therapeutics from March 2022 to November 2023. Dr. Koe also served as Executive Director, Head of Operations at Star Therapeutics from November 2019 to March 2022. Prior to joining Electra Therapeutics, Inc., Dr. Koe served as Executive Director of Technical Operations at Aravive, Inc., a biotechnology company (Aravive), from 2015 to 2019. Dr. Koe earned a Ph.D. in chemical engineering from the University of California, Los Angeles, and his B.S. in chemical engineering from the University of California, Davis.
- Kim Hien Dao
Kim Hien Dao自2024年5月起担任Electra Therapeutics，Inc.的首席医疗官，此前曾于2023年4月至2024年5月担任Electra Therapeutics，Inc.的副总裁、临床开发主管。在加入Electra Therapeutics，Inc.之前，Dao博士曾于2019年11月至2023年3月在私营制药公司Astex Pharmaceuticals, Inc.担任临床开发高级和执行医疗总监，从事实体瘤和血液恶性肿瘤的药物开发项目。Dao博士在密歇根州立大学获得生物化学和分子生物学博士学位和博士学位，并在加州大学圣地亚哥分校接受血液学医学肿瘤学培训。
Kim Hien Dao has served as Electra Therapeutics, Inc.'s Chief Medical Officer since May 2024 and previously served as Electra Therapeutics, Inc.'s Vice President, Head of Clinical Development from April 2023 to May 2024. Prior to joining Electra Therapeutics, Inc., Dr. Dao served as Senior and Executive Medical Director of Clinical Development at Astex Pharmaceuticals, Inc., a privately held pharmaceutical company, from November 2019 to March 2023, where she worked on drug development programs for solid tumors and hematological malignancies. Dr. Dao earned her D.O. and Ph.D. in biochemistry and molecular biology from Michigan State University and trained in hematology medical oncology at the University of California, San Diego.- Kim Hien Dao自2024年5月起担任Electra Therapeutics，Inc.的首席医疗官，此前曾于2023年4月至2024年5月担任Electra Therapeutics，Inc.的副总裁、临床开发主管。在加入Electra Therapeutics，Inc.之前，Dao博士曾于2019年11月至2023年3月在私营制药公司Astex Pharmaceuticals, Inc.担任临床开发高级和执行医疗总监，从事实体瘤和血液恶性肿瘤的药物开发项目。Dao博士在密歇根州立大学获得生物化学和分子生物学博士学位和博士学位，并在加州大学圣地亚哥分校接受血液学医学肿瘤学培训。
- Kim Hien Dao has served as Electra Therapeutics, Inc.'s Chief Medical Officer since May 2024 and previously served as Electra Therapeutics, Inc.'s Vice President, Head of Clinical Development from April 2023 to May 2024. Prior to joining Electra Therapeutics, Inc., Dr. Dao served as Senior and Executive Medical Director of Clinical Development at Astex Pharmaceuticals, Inc., a privately held pharmaceutical company, from November 2019 to March 2023, where she worked on drug development programs for solid tumors and hematological malignancies. Dr. Dao earned her D.O. and Ph.D. in biochemistry and molecular biology from Michigan State University and trained in hematology medical oncology at the University of California, San Diego.
- Chris Clark
Chris Clark自2026年8月起担任Electra Therapeutics，Inc.的首席财务官，并于2025年12月至2026年8月担任Electra Therapeutics，Inc.的战略和财务执行副总裁。在此之前，Clark先生曾于2007年5月至2025年5月在RS Investments担任投资组合经理、股票分析师– HealthCare，该公司是一家公众持有的投资管理公司，是一家Victory Capital投资特许公司。克拉克先生还在2004年至2007年期间担任金融服务机构TIAA CREF的研究助理，在那里他专注于全球制药。克拉克先生在弗吉尼亚大学获得经济学学士学位，是一名特许金融分析师。
Chris Clark has served as Electra Therapeutics, Inc.'s Chief Financial Officer since August 2026 and as Electra Therapeutics, Inc.'s Executive Vice President, Strategy and Finance from December 2025 to August 2026. Previously, Mr. Clark served as Portfolio Manager, Equity Analyst – HealthCare at RS Investments, a Victory Capital investment franchise, a publicly held investment management company, from May 2007 to May 2025. Mr. Clark also served as a Research Associate at TIAA CREF, a financial services organization, from 2004 to 2007, where he focused on global pharmaceuticals. Mr. Clark earned his B.A. in economics from the University of Virginia and is a chartered financial analyst.- Chris Clark自2026年8月起担任Electra Therapeutics，Inc.的首席财务官，并于2025年12月至2026年8月担任Electra Therapeutics，Inc.的战略和财务执行副总裁。在此之前，Clark先生曾于2007年5月至2025年5月在RS Investments担任投资组合经理、股票分析师– HealthCare，该公司是一家公众持有的投资管理公司，是一家Victory Capital投资特许公司。克拉克先生还在2004年至2007年期间担任金融服务机构TIAA CREF的研究助理，在那里他专注于全球制药。克拉克先生在弗吉尼亚大学获得经济学学士学位，是一名特许金融分析师。
- Chris Clark has served as Electra Therapeutics, Inc.'s Chief Financial Officer since August 2026 and as Electra Therapeutics, Inc.'s Executive Vice President, Strategy and Finance from December 2025 to August 2026. Previously, Mr. Clark served as Portfolio Manager, Equity Analyst – HealthCare at RS Investments, a Victory Capital investment franchise, a publicly held investment management company, from May 2007 to May 2025. Mr. Clark also served as a Research Associate at TIAA CREF, a financial services organization, from 2004 to 2007, where he focused on global pharmaceuticals. Mr. Clark earned his B.A. in economics from the University of Virginia and is a chartered financial analyst.
- Graham Parry
Graham Parry自2023年12月起担任Electra Therapeutics，Inc.的首席科学官。在加入Electra Therapeutics，Inc.之前，Parry博士于2023年1月至2023年12月在Star Therapeutics担任转化科学执行副总裁，在该公司的产品组合中跨职能工作，以推进多种疾病的治疗。在加入Star Therapeutics之前，Parry博士于2019年8月至2022年12月在私营临床阶段生物技术公司Third Harmonic Bio, Inc.担任转化科学高级副总裁。帕里博士在伦敦大学获得生物化学博士学位，在伦敦布鲁内尔大学获得应用生物学学士学位。
Graham Parry has served as Electra Therapeutics, Inc.'s Chief Scientific Officer since December 2023. Prior to joining Electra Therapeutics, Inc., Dr. Parry served as Executive Vice President, Translational Sciences at Star Therapeutics from January 2023 to December 2023, where he worked cross functionally across the company's portfolio to advance treatments for multiple diseases. Prior to Star Therapeutics, Dr. Parry served as Senior Vice President, Translational Sciences at Third Harmonic Bio, Inc., a privately held clinical stage biotechnology company, from August 2019 to December 2022. Dr. Parry earned a Ph.D. in biochemistry at the University of London and a B.Sc. in applied biology at Brunel University of London.- Graham Parry自2023年12月起担任Electra Therapeutics，Inc.的首席科学官。在加入Electra Therapeutics，Inc.之前，Parry博士于2023年1月至2023年12月在Star Therapeutics担任转化科学执行副总裁，在该公司的产品组合中跨职能工作，以推进多种疾病的治疗。在加入Star Therapeutics之前，Parry博士于2019年8月至2022年12月在私营临床阶段生物技术公司Third Harmonic Bio, Inc.担任转化科学高级副总裁。帕里博士在伦敦大学获得生物化学博士学位，在伦敦布鲁内尔大学获得应用生物学学士学位。
- Graham Parry has served as Electra Therapeutics, Inc.'s Chief Scientific Officer since December 2023. Prior to joining Electra Therapeutics, Inc., Dr. Parry served as Executive Vice President, Translational Sciences at Star Therapeutics from January 2023 to December 2023, where he worked cross functionally across the company's portfolio to advance treatments for multiple diseases. Prior to Star Therapeutics, Dr. Parry served as Senior Vice President, Translational Sciences at Third Harmonic Bio, Inc., a privately held clinical stage biotechnology company, from August 2019 to December 2022. Dr. Parry earned a Ph.D. in biochemistry at the University of London and a B.Sc. in applied biology at Brunel University of London.
- Quehuong Dong
Quehuong Dong自2023年10月起担任Electra Therapeutics，Inc.总裁兼首席执行官，Electra Therapeutics，Inc.董事会成员。自2023年10月起，她还担任Electra Therapeutics LLC的总裁兼首席执行官和董事会成员。从2019年4月到2023年10月，董博士担任Star Therapeutics，Inc.的首席运营官，Star Therapeutics，Inc.是一家私营生物技术公司（Star Therapeutics），她在该公司的投资组合中担任战略和运营职责。董博士还曾于2019年4月至2023年10月在私营生物技术公司Vega Therapeutics Inc.担任首席运营官。在加入Star Therapeutics之前，Dr. Dong曾在私营生物技术公司True North Therapeutics，Inc.（True North）担任商业发展副总裁。继True North被Bioverativ，Inc.（后被赛诺菲 S.A.（丨赛诺菲）收购）收购后，董博士在上市药企赛诺菲担任补体特许经营的新产品规划负责人。她通过赛诺菲从True North任职的时间为2017年3月至2019年3月。在其职业生涯的早期，董博士曾在公众持股的生物制药公司（吉利德）吉利德科学公司担任HCV市场营销总监。自2022年6月起，董博士还担任Neuron23，Inc.的董事会成员，该公司是一家私营的精准神经病学和免疫疗法公司（Neuron23）。董博士在新墨西哥大学获得了药学博士和工商管理硕士学位，并通过罗格斯大学完成了博士后研究金。
Quehuong Dong has served as Electra Therapeutics, Inc.'s President and Chief Executive Officer and a member of Electra Therapeutics, Inc.'s board of directors since October 2023. She has also served as President and Chief Executive Officer and a member of the board of managers of Electra Therapeutics LLC since October 2023. From April 2019 to October 2023, Dr. Dong served as Chief Operating Officer of Star Therapeutics, Inc., a privately held biotechnology company (Star Therapeutics), where she held strategic and operational responsibilities across the company's portfolio. Dr. Dong also served as Chief Operating Officer at Vega Therapeutics Inc., a privately held biotechnology company, from April 2019 to October 2023. Prior to Star Therapeutics, Dr. Dong served as Vice President of Commercial Development at True North Therapeutics, Inc., a privately held biotechnology company (True North). Following True North's acquisition by Bioverativ, Inc. (which was subsequently acquired by Sanofi S.A. (Sanofi)), Dr. Dong served as Head of New Product Planning for the complement franchise at Sanofi, a publicly held pharmaceutical company. Her tenure from True North through Sanofi was March 2017 to March 2019. Earlier in her career, Dr. Dong served as Director, HCV Marketing at Gilead Sciences, Inc., a publicly held biopharmaceutical company (Gilead). Dr. Dong has also served on the board of directors of Neuron23, Inc., a privately held precision neurology and immunology therapeutics company (Neuron23), since June 2022. Dr. Dong earned her Pharm.D. and M.B.A. at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University.- Quehuong Dong自2023年10月起担任Electra Therapeutics，Inc.总裁兼首席执行官，Electra Therapeutics，Inc.董事会成员。自2023年10月起，她还担任Electra Therapeutics LLC的总裁兼首席执行官和董事会成员。从2019年4月到2023年10月，董博士担任Star Therapeutics，Inc.的首席运营官，Star Therapeutics，Inc.是一家私营生物技术公司（Star Therapeutics），她在该公司的投资组合中担任战略和运营职责。董博士还曾于2019年4月至2023年10月在私营生物技术公司Vega Therapeutics Inc.担任首席运营官。在加入Star Therapeutics之前，Dr. Dong曾在私营生物技术公司True North Therapeutics，Inc.（True North）担任商业发展副总裁。继True North被Bioverativ，Inc.（后被赛诺菲 S.A.（丨赛诺菲）收购）收购后，董博士在上市药企赛诺菲担任补体特许经营的新产品规划负责人。她通过赛诺菲从True North任职的时间为2017年3月至2019年3月。在其职业生涯的早期，董博士曾在公众持股的生物制药公司（吉利德）吉利德科学公司担任HCV市场营销总监。自2022年6月起，董博士还担任Neuron23，Inc.的董事会成员，该公司是一家私营的精准神经病学和免疫疗法公司（Neuron23）。董博士在新墨西哥大学获得了药学博士和工商管理硕士学位，并通过罗格斯大学完成了博士后研究金。
- Quehuong Dong has served as Electra Therapeutics, Inc.'s President and Chief Executive Officer and a member of Electra Therapeutics, Inc.'s board of directors since October 2023. She has also served as President and Chief Executive Officer and a member of the board of managers of Electra Therapeutics LLC since October 2023. From April 2019 to October 2023, Dr. Dong served as Chief Operating Officer of Star Therapeutics, Inc., a privately held biotechnology company (Star Therapeutics), where she held strategic and operational responsibilities across the company's portfolio. Dr. Dong also served as Chief Operating Officer at Vega Therapeutics Inc., a privately held biotechnology company, from April 2019 to October 2023. Prior to Star Therapeutics, Dr. Dong served as Vice President of Commercial Development at True North Therapeutics, Inc., a privately held biotechnology company (True North). Following True North's acquisition by Bioverativ, Inc. (which was subsequently acquired by Sanofi S.A. (Sanofi)), Dr. Dong served as Head of New Product Planning for the complement franchise at Sanofi, a publicly held pharmaceutical company. Her tenure from True North through Sanofi was March 2017 to March 2019. Earlier in her career, Dr. Dong served as Director, HCV Marketing at Gilead Sciences, Inc., a publicly held biopharmaceutical company (Gilead). Dr. Dong has also served on the board of directors of Neuron23, Inc., a privately held precision neurology and immunology therapeutics company (Neuron23), since June 2022. Dr. Dong earned her Pharm.D. and M.B.A. at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University.